What are the appropriate indications, dosing, titration, contraindications, and monitoring recommendations for initiating trazodone in an adult patient?

Trazodone: Clinical Use and Prescribing Guidelines

Trazodone is FDA-approved for major depressive disorder in adults at doses of 150-400 mg daily, but should NOT be used for insomnia based on current evidence. 1

Approved Indication

Trazodone hydrochloride is indicated exclusively for the treatment of major depressive disorder (MDD) in adults 1. Despite widespread off-label use for insomnia, the 2017 American Academy of Sleep Medicine clinical practice guideline explicitly recommends against using trazodone for sleep onset or sleep maintenance insomnia (WEAK recommendation) 2. This negative recommendation stands in contrast to other agents that received positive recommendations for insomnia treatment.

Dosing and Titration

For Depression (FDA-Approved Use)

Starting and therapeutic dosing:

• Dosage range: 50-400 mg daily 3
• Optimal dosing strategy: 150 mg given predominantly at bedtime, increased as needed to 200-300 mg for full antidepressant effect 4
• Administration: Take shortly after a meal or light snack to optimize absorption 1
• Dosing schedule: Single nighttime dosing is equally effective as multiple daily doses and produces better sleep with less daytime drowsiness at treatment onset 4

Titration approach:

• Studies in elderly patients demonstrate that starting at 150 mg total daily dose (50 mg three times daily) is well-tolerated and more effective than lower starting doses of 75 mg daily 5
• Maximum tolerated doses are 300-400 mg/day in elderly patients and up to 600 mg/day in younger adults 6
• The dose-dependent profile shows sedative/anxiolytic effects at low doses (25-75 mg) and full antidepressant effects at higher doses (150-300 mg) 7

Special Populations

Elderly patients:

• Generally recommended to start at approximately 50% of adult starting dose due to increased risk of adverse drug reactions 3
• However, clinical trial data supports initiating at 150 mg daily in elderly patients with depression, as this was well-tolerated and more rapidly effective 5
• Maximum doses of 300-400 mg/day are tolerated in elderly populations 6

Hepatic impairment:

• Dose reduction required 3
• Trazodone is nearly completely metabolized hepatically 8

Renal impairment:

• Dose adjustment should be considered 3

Contraindications and Precautions

Black Box Warning

Suicidality risk: Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressants for MDD and other psychiatric disorders. Monitor closely, especially during initial treatment and dose changes 1.

Major Safety Concerns

Serotonin syndrome:

• Risk increases with concomitant use of other serotonergic drugs (SSRIs, SNRIs, triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort)
• Absolute caution with MAOIs (including linezolid) 1

Cardiovascular effects:

• Orthostatic hypotension - most significant in elderly patients 6, 9
• QTc prolongation - dose-dependent, moderate effect with risk of ventricular arrhythmias 9
• Notably lower incidence of cardiovascular effects compared to tricyclic antidepressants 6

Priapism:

• Rare but serious adverse effect requiring close monitoring 6, 9

Falls risk:

• Increased risk due to sedation and orthostatic hypotension, particularly in elderly patients 9

Bleeding risk:

• Increased when combined with aspirin, NSAIDs, antiplatelet drugs, warfarin, or other anticoagulants 1

Activation of mania/hypomania:

• Monitor for signs of mood elevation 1

Monitoring Recommendations

Initial phase (first 4-12 weeks):

• Weekly assessment for suicidal ideation and behavior, especially in patients under 25 years
• Monitor for serotonin syndrome symptoms
• Assess orthostatic vital signs, particularly in elderly patients
• Evaluate for sedation/drowsiness and fall risk

Ongoing monitoring:

• Depression severity using standardized scales (e.g., Hamilton Depression Rating Scale)
• Sleep quality and daytime functioning
• Adverse effects: sedation, dizziness, headache, nausea, blurred vision
• Cardiovascular parameters if risk factors present
• Signs of mania/hypomania activation

Before discontinuation:

• Do not abruptly discontinue; taper gradually to minimize discontinuation syndrome 1

Treatment Duration

For first episode of MDD: Continue treatment for 4-12 months after symptom remission 3

For recurrent depression: Prolonged treatment may be beneficial, as recurrence risk is approximately 50% after first episode, 70% after two episodes, and 90% after three episodes 3

Common Pitfalls to Avoid

1. Using trazodone for insomnia: Despite common practice, guideline evidence recommends against this use 2

2. Underdosing for depression: Antidepressant efficacy requires 150-300 mg daily; lower doses (25-75 mg) provide only sedative/anxiolytic effects 7

3. Ignoring food requirements: Absorption is optimized when taken with food; advise patients to take shortly after a meal or light snack 1

4. Overlooking orthostatic hypotension in elderly: This is the most clinically significant adverse effect in older adults and increases fall risk 6, 9

5. Combining with multiple serotonergic agents: Carefully evaluate all concomitant medications for serotonin syndrome risk 1

6. Abrupt discontinuation: Always taper to avoid withdrawal symptoms 1

Advantages Over Other Antidepressants

• Low anticholinergic effects: Significantly fewer than tricyclic antidepressants 3, 8, 9
• Sexual function: Low risk of sexual dysfunction 7
• Weight neutral: Does not typically cause weight gain 7
• Safety in overdose: Relatively safe compared to tricyclic antidepressants; no deaths reported with trazodone alone 8, 6
• Cardiac conduction: Suitable for patients with cardiac conduction disturbances 8